Ayala Pharmaceuticals (ADXS) Competitors $0.03 -0.08 (-74.77%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends ADXS vs. CNSP, CELZ, GHSI, BCDA, FRTX, BFRI, KTTA, SNOA, CPHI, and THARShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include CNS Pharmaceuticals (CNSP), Creative Medical Technology (CELZ), Guardion Health Sciences (GHSI), BioCardia (BCDA), Fresh Tracks Therapeutics (FRTX), Biofrontera (BFRI), Pasithea Therapeutics (KTTA), Sonoma Pharmaceuticals (SNOA), China Pharma (CPHI), and Tharimmune (THAR). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. CNS Pharmaceuticals Creative Medical Technology Guardion Health Sciences BioCardia Fresh Tracks Therapeutics Biofrontera Pasithea Therapeutics Sonoma Pharmaceuticals China Pharma Tharimmune Ayala Pharmaceuticals (NASDAQ:ADXS) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings. Which has higher valuation and earnings, ADXS or CNSP? CNS Pharmaceuticals has lower revenue, but higher earnings than Ayala Pharmaceuticals. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAyala Pharmaceuticals$10K115.10-$48.07M-$7.980.00CNS PharmaceuticalsN/AN/A-$18.85M-$74.970.00 Which has more volatility & risk, ADXS or CNSP? Ayala Pharmaceuticals has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Is ADXS or CNSP more profitable? Company Net Margins Return on Equity Return on Assets Ayala PharmaceuticalsN/A N/A N/A CNS Pharmaceuticals N/A N/A -515.32% Do analysts prefer ADXS or CNSP? CNS Pharmaceuticals has a consensus target price of $0.50, suggesting a potential upside of 279.65%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CNS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ADXS or CNSP? In the previous week, CNS Pharmaceuticals had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 1 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat CNS Pharmaceuticals' score of -0.15 indicating that Ayala Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CNS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in ADXS or CNSP? 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community prefer ADXS or CNSP? CNS Pharmaceuticals received 47 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 71.21% of users gave CNS Pharmaceuticals an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAyala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes62100.00% CNS PharmaceuticalsOutperform Votes4771.21% Underperform Votes1928.79% SummaryCNS Pharmaceuticals beats Ayala Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio0.004.9791.2813.60Price / Sales115.10371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book-0.0110.306.906.33Net Income-$48.07M$153.61M$118.83M$225.93M7 Day PerformanceN/A-1.73%-1.92%-0.96%1 Month PerformanceN/A-7.26%-3.75%1.06%1 Year PerformanceN/A31.10%31.37%26.59% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03-74.8%N/A-96.7%$1.15M$10,000.000.0020Analyst ForecastNews CoverageGap DownCNSPCNS Pharmaceuticals1.6074 of 5 stars$0.13+6.6%$0.50+279.7%-99.9%$4.41MN/A0.005Gap UpHigh Trading VolumeCELZCreative Medical Technology1.7223 of 5 stars$2.49-2.4%N/A-41.6%$4.36M$10,000.00-0.675Analyst RevisionPositive NewsGap DownGHSIGuardion Health SciencesN/A$3.22-2.1%N/A-43.4%$4.35M$12.25M0.6610Gap DownBCDABioCardia3.0529 of 5 stars$2.03+2.0%$25.00+1,131.5%-81.6%$4.30M$480,000.00-0.4916Analyst RevisionGap UpFRTXFresh Tracks TherapeuticsN/A$0.72flatN/A-9.5%$4.27M$8.01M0.0020BFRIBiofrontera2.5806 of 5 stars$0.74-4.8%$7.00+843.0%-76.9%$4.11M$34.07M-0.3570Analyst RevisionGap DownKTTAPasithea Therapeutics1.3086 of 5 stars$3.14-1.6%N/A-50.4%$3.99M$20,000.000.003News CoverageGap DownSNOASonoma Pharmaceuticals0.839 of 5 stars$2.96+4.2%N/A+1,381.5%$3.97M$12.73M0.00180CPHIChina PharmaN/A$0.20+3.9%N/A-59.6%$3.84M$7.01M0.00231THARTharimmune0.8279 of 5 stars$2.55+2.0%N/A-96.1%$3.80MN/A0.002 Related Companies and Tools Related Companies CNS Pharmaceuticals Alternatives Creative Medical Technology Alternatives Guardion Health Sciences Alternatives BioCardia Alternatives Fresh Tracks Therapeutics Alternatives Biofrontera Alternatives Pasithea Therapeutics Alternatives Sonoma Pharmaceuticals Alternatives China Pharma Alternatives Tharimmune Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADXS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
